×
Customize
?
Start
Cancer Types
Quick Links
Events
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Leukemia
Katie Kosko
With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.
Dr. Matthew Davids
Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.
Kristie L. Kahl
Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.
Jessica Skarzynski
As 2019 comes to a close, take a read through CURE®’s top stories of the year.
Naval Daver, MD
New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.
Rachelle Berfond
When one woman experienced symptoms of chronic lymphocytic leukemia, people blamed her nerves and told her to rest. Instead, she listened to her body.
Tom Castles
Patients aged 55 and over remained in remission after receiving CC-486, according to phase 3 study findings.
Beth Fand Incollingo
Whole genome sequencing of blood and bone marrow from patients with acute myeloid leukemia and myelodysplastic syndrome has revealed previously unknown disease subtypes.
Katie Kosko
In a phase 3 clinical trial, Blincyto (blinatumomab), a type of immunotherapy, improved survival and showed fewer side effects in young patients.
Tom Castles
Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.